Abstract
Osteonecrosis of the femoral head (ONFH) is a common osteological disease. Treatment of ONFH prior to the collapse of the femoral head is critical for increasing therapeutic efficiency. Tissue engineering therapy using bone mesenchymal stem cells (BMSCs) combined with a scaffold is a promising strategy. However, it is currently unclear how to improve the efficiency of BMSC recruitment under such conditions. In the present study, a specific cyclic peptide for Sprague‑Dawley rat BMSCs, CTTNPFSLC (known as C7), was used, which was identified via phage display technology. Its high affinity for BMSCs was demonstrated using flow cytometry and fluorescence staining. Subsequently, the cyclic peptide was placed on β‑tricalcium phosphate (β‑TCP) scaffolds using absorption and freeze‑drying processes. Adhesion, expansion and proliferation of BMSCs was investigated in vitro on the C7‑treated β‑TCP scaffolds and compared with pure β‑TCP scaffolds. The results revealed that C7 had a promoting effect on the adhesion, expansion and proliferation of BMSCs on β‑TCP scaffolds. Therefore, C7 may be effective in future tissue engineering therapy for ONFH.